Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.42 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.42 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.42 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.42 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13174125 | 0.90 | MEN1 (0.44) | MEN1KMT2ACYP1B1CYP1A1MAPT | |
| SCHEMBL15729859 | 0.84 | NPC1 (0.57) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL13975280 | 0.83 | KLK3 (0.55) | KMT2AMAPTCYP3A4ALDH1A1HPGD | |
| SCHEMBL28233679 | 0.79 | MAPT (0.56) | MEN1KMT2AMAPTGAAALDH1A1 | |
| SCHEMBL15813696 | 0.73 | SMN1; SMN2 (0.41) | MEN1KMT2AMAPTGAACYP1A2 | |
| SCHEMBL31510906 | 0.72 | KMT2A (0.52) | MEN1KMT2ACYP1B1CYP1A1CYP1A2 | |
| SCHEMBL25409385 | 0.71 | KLK3 (0.57) | CYP2A6KLK3 | |
| SCHEMBL2684806 | 0.71 | LOX (0.42) | MAPTKLK3 | |
| SCHEMBL13596557 | 0.71 | CYP19A1 (0.50) | MEN1KMT2A | |
| SCHEMBL167998 | 0.71 | SMN1; SMN2 (0.56) | MEN1KMT2AMAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2516437-B1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| EP-2516437-B1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| EP-2516437-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| CN-102762560-A | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG | 2012-10-31 | — | — | CN | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| WO-2011076744-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076744-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | CYP4F2, CYP11B2, CYP4F3 | MEN1 657/4885KMT2A 2606/4885CYP1B1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.